US Hospital Pricing Lead

ROLE SUMMARY

The US Hospital Pricing Lead is a significant, cross-functional role that collaboratively partners among the US Hospital Commercial Team, Portfolio, PCO, Account Management, Finance, PGS, etc. to maximize the performance of the US HBU business and deliver on the organization's strategic goals through best in class pricing strategies.

The position is primarily an Individual Contributor that is a highly engaged member of the US Commercial Organization, providing leadership/ownership of the US Commercial Pricing Policy.

The US Hospital Pricing Lead will govern the creation and implementation of the US Commercial Pricing Policy, lead bi-monthly US Pricing Committee meetings, the Bi-Annual List Price process, and serve as a pan-Portfolio pricing czar to ensure optimal contract and pricing efficiencies are maintained.  The position may also be responsible to directly or indirectly lead projects / initiatives to develop tools, analytics, reports related to optimizing US pricing strategy.

The successful candidate will be self-driven with strong business acumen and can-do attitude; demonstrate the ability to interface, communicate effectively, and build relationships with all levels within the organization; and be highly focused on driving effectiveness, efficiency and continuous improvement by enhancing and improving the analytics capabilities within US HBU.  He/she will be analytical, organized, and knowledgeable about our market and business.  He/she will have proven expertise working in a complex environment and navigating a matrixed organization to drive constructive dialog/debate, support strong decision-making, secure support, and drive alignment.

ROLE RESPONSIBILITIES

The US Hospital Pricing Lead responsibilities include but are not limited to:

• Developing and recommending pricing/contracting strategies and alternatives across the US Hospital Injectables & Surgical Portfolio; applying deep expertise of the US HBU portfolio and market to support those recommendations with analytics; and monitoring the success (or recommending modification) of those strategies to enable the business to deliver on its commitments - driving our value proposition with customers, growing revenue, capitalizing on market events, and using data to support making the best decisions for Pfizer

• Gaining and leveraging understanding of key customers to develop practical and effective pricing recommendations to drive successful customer strategies and responses (i.e. for RPFs, price challenges, etc.) and contracting decisions, while also striving to streamline decision-making to quickly respond to customer requests

• Utilize NEO Dashboard and other tools to analyze, interpret, and translate data into actionable insights and recommendations to drive incremental revenue and margin through strategic pricing initiatives and contract strategies

• Creation and management of the US Hospital Pricing Committee to effectively govern pricing decisions across the business unit.

• Implementation and management of US Hospital Pricing policy across all commercial contracts

• Remaining well-informed of emerging external trends and market dynamics to identify signals in the marketplace that could impact our business

• Managing the bi-annual List Price process across the Global Hospital and Biosimilar organization.  Collaborating with Portfolio Leads to provide guidance and recommendations on Pfizer’s list prices to accommodate best-in-class pricing and contracting strategies, optimizing gross-to-net, and managing risks such as 340B discounts, IRA penalties, and external factors.

• Supporting the Go-To-Market process by leading market analyses and developing pricing/strategy recommendations for new product launches, private label launches, return to markets and line extensions

• ideating, developing, redesigning, and/or enhancing key analytics tools, reports, and processes with an eye toward driving optimized pricing and contracting strategies

• being a highly engaged strategic thinker who operates with an entrepreneurial mindset and in a fully compliant manner to summarize and maximize the performance of the Ig and Surgical portfolios and th